Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danvatirsen +/- Durvalumab in Japanese Patients with Advanced Solid Malignancies
NCT03394144Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2018
- Primary completion
- Apr 2019
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of danvatirsen in solid tumor (advanced stage) (2 arms), sponsored by AstraZeneca. Primary endpoint: Safety and tolerability in terms of adverse events up to 12 months. Started Jan 2018; status: completed.
02
Drugs
danvatirsen
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03394144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03394144.